Delivery Order SPE2DB22D3401-SPE2DB25FT1MZ

Award Date 1/7/25
Potential Completion Date 1/8/25
Potential Value $11K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,506.28 firm fixed-price contract is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of October 13, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $29,842.39 firm fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S and has an ultimate completion date of August 16, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $30,275.13 firm fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a period of performance through January 13, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,214.30 firm fixed-price contract is for the delivery of XIFAXAN 550 mg tablets, a prescription medication. The contract has a period of performance through July 1, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,287.82 firm fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, with a period of performance through January 18, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award with ID SPE2DB22D2206|SPE2DB25FEG40 was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $11,858.31 firm fixed price delivery order is for the supply of XIFAXAN 550 MG TABLET UD 60S, a pharmaceutical product. The contract has an ultimate completion date of November 18, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,408.47 firm-fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET UD 60S, a prescription medication. The contract has an ultimate completion date of November 20, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,392.21 firm fixed-price delivery order is for XIFAXAN 550 MG TABLET 60S, with a completion date of August 15, 2024. The contract was not set aside for any specific business type. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of XIFAXAN 550 mg tablets. The $13,486.05 firm fixed-price delivery order has an ultimate completion date of December 4, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products...
This federal contract award, valued at $7,038.50, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a specialty medication, with a completion date of June 5, 2023. This award is a delivery order under Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026....
  • SPE2DB22D3401
    Indefinite Delivery Contract
  • SPE2DB22D3401-SPE2DB25FT1MZ
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,208.56 firm fixed-price delivery order contract covers the supply of XIFAXAN 550 MG TABLET 60S, a prescription medication, with a period of performance through January 8, 2025.

Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific delivery order award is not designated with a set-aside requirement, indicating open competition.

Generated 4/13/25, 12:49 AM